(0.05%) 5 520.00 points
(0.10%) 39 884 points
(0.16%) 19 783 points
(0.01%) $81.64
(0.46%) $2.82
(-0.34%) $2 336.40
(-0.05%) $29.51
(0.27%) $1 004.50
(0.03%) $0.932
(0.02%) $10.54
(0.01%) $0.788
(-0.56%) $87.50
-13.39% $ 0.0401
Live Chart Being Loaded With Signals
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 4.04M |
Średni wolumen | 2.24M |
Kapitalizacja rynkowa | 2.95M |
EPS | $0.280 ( Q3 | 2023-11-09 ) |
Następna data zysków | ( $0 ) 2024-08-19 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0528 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0130 (32.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-04-10 | Petrini Maria Carolina | Buy | 400 000 | Nonqualified Stock Option (Right to Buy) |
2023-04-10 | Petrini Maria Carolina | Buy | 0 | |
2023-02-01 | Mcintyre Gail Frances | Buy | 700 000 | Stock Option (Right to Buy) |
2023-02-01 | Geller Robert B. | Buy | 400 000 | Stock Option (Right to Buy) |
2023-02-01 | Howard Rudy | Buy | 400 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 72 486 477 | Sell: 119 333 |
Wolumen Korelacja
Aravive Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Aravive Inc Korelacja - Waluta/Towar
Aravive Inc Finanse
Annual | 2022 |
Przychody: | $9.14M |
Zysk brutto: | $-57.80M (-632.60 %) |
EPS: | $-2.22 |
FY | 2022 |
Przychody: | $9.14M |
Zysk brutto: | $-57.80M (-632.60 %) |
EPS: | $-2.22 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.48 |
FY | 2020 |
Przychody: | $5.69M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.930 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Aravive Inc
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej